The National Cancer Research Institute adopted this new technology to support its mission of advancing knowledge in cancer prevention, diagnosis and therapy for cancer control. Progenesis SameSpots offers a major breakthrough in the analysis of 2D single stain and DIGE images, creating new possibilities for 2D based proteomics research.
The new technology has shown its value. Dr. Kondo and his group are identifying biomarker candidates for prediction of response to the chemotherapy (gefitinib, Iressa) in lung adenocarcinoma using Progenesis SameSpots. This is important research because in Japan, while the incidence of stomach cancer is decreasing those of lung, colorectal and breast cancers are increasing.
Dr. Kondo also discovered biomarker candidates for prediction of early metastasis post surgery in gastrointestinal stromal tumor (GIST). Dr. Kondo said, “We will be able to select the patients who are destined to have recurrence and improve their clinical outcome by adjuvant chemotherapy."
Dr. Kondo and his team are developing biomarkers to predict the lymph node metastasis in esophageal cancer, the early recurrence in hepatocellular carcinoma, and the response to neo-adjuvant chemotherapy in osteosarcoma. Prediction performance of the identified biomarkers is extensively validated in a clinical-scale sample set in his laboratory.
The image alignment of SameSpots offers users a streamlined 2D workflow, largely through the elimination post analysis editing. This speeds up the 2D analysis process and reduces the subjectivity which user-operated editing introduces.